OncoSil PanCO Clinical Trial Presented at ESMO World Congress on Gastrointestinal Cancer (WCGIC) focusing on resected and non-resected participant data
Sydney, Australia, 29 June 2022: OncoSil Medical Limited (ASX: OSL) (OncoSil or the Company) is pleased to announce that the Principal Investigator of the PanCO study will be presenting both an oral and poster presentation at the ESMO World Congress on Gastrointestinal Cancer (WCGIC) on 29 June 2022. The presentation is titled “Comparison of resected vs. non-resected patients with unresectable locally advanced pancreatic cancer (LAPC) receiving P-32 microparticles with gemcitabine/nab-paclitaxel or FOLFIRINOX chemotherapy in the PanCO study”. The presentation focuses upon data in the resected and non-resected participants in the PanCO Study. The presenter is Dr Paul Ross, Consultant Medical Oncologist from Guy’s & St Thomas’ Hospital NHS Foundation Trust, London and Principal Investigator of the PanCO study.
OncoSil’s CEO and Managing Director, Mr Nigel Lange said:
“We are delighted to be able to present additional data from our PanCO Study, comparing the baseline characteristics and outcomes in the participants who went on to have surgical resection compared to those who did not. This new analysis shows that the resected participants had a substantial response to treatment before they underwent surgery. These clinical findings have motivated increased interest from Hepato-Pancreatico-Billary (HPB) surgeons who have been encouraged by the reduction in tumour volumes following treatment. Reduction of tumour volume may increase the potential for surgical resection and may be linked with the encouraging survival of the resected cohort of patients being administered the OncoSilTM device.”